BACKGROUND INFORMATION ON THE PROCEDURE  
1. 
Submission of the dossier 
The  company  Sanofi  Pharma  Bristol-Myers  Squibb  SNC  submitted  on  27  September  1996  an 
application  for  Marketing  Authorisation  to  the  European  Medicines  Evaluation  Agency  (EMEA) 
through the centralised procedure. After agreement by the CPMP, this medicinal product was referred 
to Part B of the Annex to Council Regulation EEC No 2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur: 
F. de Andrés-Trelles 
Co-Rapporteur:  C.Strömberg 
Licensing status 
The  product  was  not  licensed  in  any  country  outside  the  EU  at  the  time  of  submission  of  the 
application. 
Steps taken for the assessment of the product 
An application for marketing authorisation was submitted to the EMEA on 27 September 1996. 
The centralised procedure started on 21 October 1996. 
The Rapporteur’s assessment report was circulated to all CPMP Members on 16 January 1997. 
The  Co-Rapporteur’s  assessment  report  was  circulated  to  all  CPMP  Members  on  9  January 
1997. 
The Rapporteur’s and Co-Rapporteur’s assessment reports and the comments from other CPMP 
Members  were  discussed  during  the  CPMP  meeting  in  February  1997  and  the  CPMP 
consolidated list of questions was adopted on 19 February 1997. 
An  inspection  of  the  manufacturing  site  of  the  finished  medicinal  product  at  Bristol-Myers 
Squibb Company (2400 West Lloyd Expressway, Evansville, Indiana, 47721-001, United States 
of America) was carried out by the Inspection Services of France and of the United Kingdom on 
17-19 March 1997. 
The responses to the consolidated list of questions were provided on 6 March 1997. 
The joint Rapporteur’s and Co-Rapporteur’s assessment report on the responses provided by the 
applicant was sent to all CPMP Members on 9 April 1997. 
Additional  information  regarding  quality  issues  together  with  an  updated  version  of  the 
Summary  of  Product  Characteristics,  Package  Leaflet  and  Labelling,  were  provided  by  the 
applicant on 30 April 1997.  
Comments  from  other  CPMP  Members  were  received  by  5  May  1997,  and  the  Rapporteur 
circulated  on  8  May  1997  a  summary  addressing  outstanding  quality,  preclinical  and  clinical 
issues.  An  updated  version  of  the  Summary  of  Product  Characteristics,  Package  Leaflet  and 
Labelling, were also included for discussion at the CPMP May meeting.  
During the May CPMP meeting, the final wording regarding the posology to be introduced in 
the Summary of Product Characteristics was fully discussed and agreed by the CPMP. 
In  the  light  of  the  overall  data  submitted  and  scientific  discussion  within  the  Committee,  the 
CPMP  issued  a  positive  opinion  for  granting  a  Marketing  Authorisation  to  Aprovel  on 
15 May 1997. 
The  CPMP  opinion  was  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European  Commission  on  10  June  1997,  which  adopted  the  corresponding  Decision  on  
27 August 1997. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
II 
1/1 
EMEA 2004 
 
 
